// App-Quantinova.ai

TPS5608 : ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

Researchers

Presenter

  • Toon Van Gorp

Principal Investigators

  • Alain Lortholary

  • David Cibula

  • Axel Walther

  • Antonella Savarese

  • Maria Pilar Barretina-Ginesta

  • Firat Orta

  • Lubomir Bodnar

  • Chyong-Huey Lai

  • Jacob Korach

  • Christian Marth

  • Kosei Hasegawa

  • Xing Xie

  • Emma L. Barber

  • Robert L. Coleman

  • Stephen Michael Keefe

  • Robert Orlowski

  • Brian Slomovitz

  • Christos Papadimitriou

Medical Centers

  • KU Leuven, Leuven, Belgium

  • NSGO & Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark

  • Centre Catherine de Sienne, Hôpital Privé du Confluent, Nantes, France

  • Department of Obstetrics and Gynecology, General Faculty Hospital in Prague, First Faculty of Medicine, Charles University, Prague, Czech Republic, Bristol Cancer Institute, University Hospitals Bristol, Bristol, United Kingdom

  • IRCCS Istituto Nazionale Tumori Regina Elena - Ifo, Rome, Italy

  • Catalan Institute of Oncology and Girona Biomedical Research Institute, Medical School University of Girona, Girona, Spain

  • Ankara University School of Medicine, Pharmacology, Ankara, Turkey

  • Department of Oncology and Immunooncology, Warmian-Masurian Cancer Center of the Ministry of the Interior and Administration’s Hospital, Olsztyn, Poland

  • TGOG and Department of Gynecology and Obstetrics, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan, Gynecologic Oncology Department, Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

  • Department for Radiology, Medical University Innsbruck, Innsbruck, Austria

  • Department of Gynecologic Oncology, Saitama Medical University, Hidaka, Saitama Prefecture, Japan

  • The Children 's Hospital Zhejiang University School of Medicine, Hangzhou, China

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • US Oncology Research, The Woodlands, TX

  • Merck & Co., Inc., Kenilworth, NJ, Broward Health, Fort Lauderdale, FL, Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece

Locations

  • Belgium

  • Denmark

  • France

  • United Kingdom

  • Italy

  • Spain

  • Turkey

  • Poland

  • Israel

  • Austria

  • Japan

  • China

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

  • Solid malignancies

Biomarkers

  • p53

  • Cluster of Differentiation 206

  • Programmed death-ligand 1

  • DNA mismatch repair status

Drug/Treatment

  • Pembrolizumab

  • Carboplatin

  • Paclitaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

Phase

  • III

Study Id's

  • NCT04634877

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved